Sarepta (SRPT) Closer to Approval with Latest Dataset - RBC Capital

RBC Capital analyst Simos Simeonidis reiterated an Outperform rating and $62 price target on Sarepta Therapeutic (NASDAQ: SRPT) after the company revealed new data. The analyst said even though still small and not perfect, its looks better than prior iterations, and lends to approvable.

Simeonidis commented, " Sarepta presents larger safety dataset included in NDA. Sarepta hosted a call and panel discussion with DMD KOL’s this morning to go over the full data package submitted to FDA. The highlights of the NDA package include 1) 192-week 6MWT data that is now compared to matched natural history controls, 2) 4th biopsy results which were assayed under protocols developed in close collaboration with FDA, and 3) 192-week safety data. SRPT will present these same results during a symposium today (12:30 pm ET) at the International Congress of the World Muscle Society (WMS) in Brighton, UK. We view these new results and analysis as significantly improving the overall data package for eteplirsen, and we continue to anticipate FDA accelerated approval by the Feb 2016 PDUFA."

For an analyst ratings summary and ratings history on Sarepta Therapeutic click here. For more ratings news on Sarepta Therapeutic click here.

Shares of Sarepta Therapeutic closed at $32.11 yesterday.

For an analyst ratings summary and ratings history on Sarepta Therapeutic click here. For more ratings news on Sarepta Therapeutic click here.

Shares of Sarepta Therapeutic closed at $32.11 yesterday.

You May Also Be Interested In

• RBC Capital Starts Northview Residential REIT (NRR-U:CN) at Sector Perform
• Kepler Cheuvreux Downgrades Telecom Italia SpA (TIT:IM) (TI) to Hold
• Canaccord Starts Elixir Energy Ltd (EXR:AU) at Spec. Buy